CC
ALNY icon

Centiva Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Centiva Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-42
Closed -$11.6K – 1641
2024
Q3 		$11.6K Sell
42
-958
-96% -$249K ﹤0.01% 2049
2024
Q2 		$243K Buy
+1,000
New +$158K ﹤0.01% 1585
2023
Q4 		– Sell
-421
Closed -$74.6K – 1758
2023
Q3 		$74.6K Buy
+421
New +$80.3K ﹤0.01% 1561
2022
Q4 		– Sell
-456
Closed -$91K – 1345
2022
Q3 		$91K Buy
+456
New +$87K ﹤0.01% 1297
2022
Q2 		– Sell
-2,594
Closed -$368K – 1660
2022
Q1 		$424K Buy
+2,594
New +$395K 0.01% 1050
2021
Q4 		– Sell
-1,731
Closed -$327K – 1162
2021
Q3 		$327K Sell
1,731
-2,945
-63% -$552K 0.02% 757
2021
Q2 		$793K Buy
+4,676
New +$685K 0.02% 664
2021
Q1 		– Sell
-3,296
Closed -$428K – 1132
2020
Q4 		$428K Buy
3,296
+94
+3% +$12.6K 0.02% 509
2020
Q3 		$466K Buy
3,202
+499
+18% +$70.9K 0.03% 368
2020
Q2 		$400K Buy
2,703
+2,141
+381% +$289K 0.02% 342
2020
Q1 		$61K Buy
562
+306
+120% +$35.3K ﹤0.01% 534
2019
Q4 		$29K Sell
256
-1,169
-82% -$117K ﹤0.01% 778
2019
Q3 		$115K Buy
+1,425
New +$113K 0.01% 546

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Centiva Capital's ALNY Position: Q4 2024 in Review

Centiva Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 42 shares — an estimated $11.6K sold.

Centiva Capital first reported a position in ALNY in Q3 2019 and held it in 13 quarters. The position peaked at $793K in Q2 2021. 595 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

  • Centiva Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 42 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $11.6K.
  • Centiva Capital first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 13 quarters.
  • Centiva Capital's Alnylam Pharmaceuticals position peaked at $793K in Q2 2021.
  • 595 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.